SPECT/CT PROSTASCINT imaging guides prostate cancer therapy

11/4/2009 | Reuters

SPECT/CT images of PROSTASCINT, a monoclonal antibody attached to the radioisotope Indium-111 for specific targeting of prostate-specific membrane antigen, helped identify areas that needed increased doses of radioactive seeds in patients at risk for metastatic prostate cancer. The images also helped in evaluating for biochemical disease-free survival by showing the presence or absence of lymph node metastases.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA